Tumor NGS results were still pending, and his liquid biopsy (FoundationOne® Liquid CDx; Foundation Medicine, Inc., Cambridge, MA, USA) showed a low ctDNA tumor fraction (<1%) and detectable mutations in DNMT3A and TET2 suspicious for clonal hematopoiesis. This evidence concerns the gene DNMT3A and neoplasm.